doi:10.19982/j.issn.1000-6621.20240141

Abstract

CLC Number:

Figures/Tables 2

References 25

[1]	何彦安, 丁辉, 蔡岷, 等. 胆管结核误诊为壶腹周围癌一例并文献复习. 临床误诊误治, 2014, 27(7):42-44. doi:10.3969/j:issn.1002-3429.2014.07.016.
[2]	李建水, 张肇达, 唐勇. 1例肝门胆管结核及临床分析. 消化外科, 2005, 4(4):249-264. doi:10.3760/cma.j.issn.1673-9752.2005.04.028.
[3]	Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep, 2020, 47(5):4065-4075. doi:10.1007/s11033-020-05413-7.
[4]	Zampieri D, Mamolo MG. Hybridization Approach to Drug Discovery Inhibiting Mycobacterium tuberculosis-An Overview. Curr Top Med Chem, 2021, 21(9):777-788. doi:10.2174/1568026620666200819151342.
[5]	丁芹, 陈薇, 张胜康, 等. 肺外结核患者的营养状况调查及影响因素分析. 中国防痨杂志, 2023, 45(9):839-844. doi:10.19982/j.issn.1000-6621.20230221.
[6]	Fan ST, Ng IO, Choi TK, et al. Tuberculosis of the bile duct: a rare cause of biliary stricture. Am J Gastroenterol, 1989, 84(4):413-414. pmid: 2929563
[7]	Alsawat KE, Aljebreen AM. Resolution of tuberculous biliary stricture after medical therapy. World J Gastroenterol, 2006, 12(7):1153-1156. doi:10.3748/wjg.v12.i7.1153.
[8]	张蕊, 时倩倩, 王仲秋. DCE-MRI、DWI和MRCP联合诊断肝外胆管癌临床价值研究. 实用肝脏病杂志, 2023, 26(6):923-926. doi:10.3969/j.issn.1672-5069.2023.06.039.
[9]	王宏博, 杨业发, 葛乃建. 肝外胆管癌的介入治疗现状与展望. 中国癌症杂志, 2022, 32(2):118-124. doi:10.19401/j.cnki.1007-3639.2022.02.003.
[10]	Ozin Y, Parlak E, Kilic ZM, et al. Sclerosing cholangitis-like changes in hepatobiliary tuberculosis. Turk J Gastroenterol, 2010, 21(1):50-53. doi:10.4318/tjg.2010.0049. pmid: 20533114
[11]	Dyson JK, Beuers U, Jones D, et al. Primary sclerosing cholangitis. Lancet, 2018, 391(10139):2547-2559. doi:10.1016/S0140-6736(18)30300-3. pmid: 29452711
[12]	Ch’Ng LS, Amzar H, Ghazali KC, et al. Imaging appearances of hepatic tuberculosis: experience with 12 patients. Clin Radiol, 2018, 73(3):311-321. doi:10.1016/j.crad.2017.10.016.
[13]	Karaosmanoglu AD, Onur MR, Sahani DV, et al. Hepatobiliary Tuberculosis: Imaging Findings. AJR Am J Roentgenol, 2016, 207(4):694-704. doi:10.2214/AJR.15.15926.
[14]	徐绽蕾, 邵国良. 肝外胆管细胞癌的影像学诊断现状与展望. 医学影像学杂志, 2020, 30(10):1936-1939.
[15]	Manfredi R, Barbaro B, Masselli G, et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis, 2004, 24(2):155-164. doi:10.1055/s-2004-828892. pmid: 15192788
[16]	方伟军, 韩远远, 宋敏, 等. 陈旧性肺结核复燃的CT征象分析. 新发传染病电子杂志, 2021, 6(1):45-48. doi:10.19871/j.cnki.xfcrbzz.2021.01.010.
[17]	Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis, 2015, 32:87-93. doi:10.1016/j.ijid.2014.12.007. pmid: 25809762
[18]	赵艳丽, 车南颖. 《结核病病理学诊断规范》团体标准解读. 中国防痨杂志, 2024, 46(4):371-374. doi:10.19982/j.issn.1000-6621.20240074.
[19]	中华医学会结核病学分会,结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6):419-425. doi:10.3760/cma.j.issn.1001-0939.2017.06.005.
[20]	Mazlan MKN, Mohd Tazizi MHD, Ahmad R, et al. Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach. Antibiotics (Basel), 2021, 10(8):908. doi:10.3390/antibiotics10080908.
[21]	袁媛, 卢水华. 《世界卫生组织结核病整合指南模块4:药物敏感结核病的治疗》解读. 中国防痨杂志, 2022, 44(11):1122-1125. doi:10.19982/j.issn.1000-6621.20220330.
[22]	Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One, 2011, 6(7):e21836. doi:10.1371/journal.pone.0021836.
[23]	Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings. Radiographics, 2019, 39(7):2023-2037. doi:10.1148/rg.2019190109. pmid: 31697616
[24]	董裕, 张福真, 尚媛媛, 等. GeneXpert MTB/RIF Ultra在肺外结核诊断中的研究进展. 中国防痨杂志, 2023, 45(12):1193-1197. doi:10.19982/j.issn.1000-6621.20230357.
[25]	Meehan CJ, Goig GA, Kohl TA, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol, 2019, 17(9):533-545. doi:10.1038/s41579-019-0214-5. pmid: 31209399

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 25

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.